Cyrille Touzeau

机构：Centre National de la Recherche Scientifique, Inserm, Centre Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Nantes Université · ORCID：0000-0003-0275-2575

发表论文 510 篇 · 总被引 12732 次 · h-index 51

代表论文

• Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial (2026 · The Lancet Oncology · 被引 39)
• Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network (2025 · HemaSphere · 被引 10)
• A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a (2025 · Blood · 被引 9)
• Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma (2025 · Blood · 被引 8)
• Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial (2025 · Blood · 被引 3)
• Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 3)